JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?

Johnson & Johnson (JNJ) surpassed Q2 estimates and increased its 2025 guidance, while AstraZeneca (AZN) met EPS forecasts and maintained its outlook. Post-results, JNJ is positioned as the stronger investment, offering superior growth visibility, a lower forward P/E of 14.80 versus AZN's 15.11, and a more attractive 3.2% dividend yield compared to AZN's 2.8%. Despite challenges like Stelara's loss of exclusivity and China's VBP impact, JNJ's diversified portfolio and pipeline are expected to drive accelerated growth from 2026, leading to a Zacks Rank #2 (Buy) recommendation over AZN's #3 (Hold).

Analysis

Following second-quarter results, Johnson & Johnson (JNJ) and AstraZeneca (AZN) present diverging near-term outlooks. JNJ surpassed Q2 earnings and sales estimates and raised its full-year 2025 guidance, signaling strong operational momentum. Its Innovative Medicine sales grew 2.4% organically despite a significant 42.7% Q2 sales decline for Stelara following its loss of exclusivity, and the MedTech segment's sales rose 6.1%. In contrast, AZN met EPS estimates but only maintained its outlook, facing immediate headwinds from US generic competition for Brilinta and Soliris, pricing pressure from the Part D redesign, and the potential inclusion of its key drug Farxiga in China's volume-based procurement (VBP) program. While AZN's oncology franchise remains a powerful growth engine, with sales up 16% in H1 2025, and has ambitious long-term revenue targets of $80 billion by 2030, JNJ appears better positioned in the immediate term. JNJ's 2025 EPS consensus estimate saw a more substantial upward revision to $10.86 compared to AZN's modest increase to $4.54. Furthermore, JNJ offers a more attractive valuation with a forward P/E of 14.80 versus AZN's 15.11, and a superior dividend yield of 3.2% against AZN's 2.8%, reinforcing its comparatively stronger position despite its own challenges with China's VBP and talc litigation.

Key Decisions for Investors

• Given its Q2 beat-and-raise, more significant upward earnings revisions, and superior dividend yield of 3.2%, investors may find Johnson & Johnson a more compelling near-term investment for a blend of growth and income compared to AstraZeneca.
• Investors holding or considering JNJ should closely monitor the pace of sales erosion from the Stelara patent cliff and the impact of China's VBP program on MedTech revenues, as these are the key identified risks to its growth trajectory.
• For AstraZeneca, caution is warranted due to a confluence of near-term pressures, including new US generic competition for key drugs and pricing headwinds, which may temper the otherwise strong performance of its oncology and new product pipeline.
• While both companies trade at a premium to the industry, JNJ's slightly lower forward P/E ratio of 14.80 presents a marginally better valuation entry point relative to AZN at 15.11.